Oncology News

Florida-based Digital Blue Dog have signed an agreement to exclusively represent DBD's Oncology Network, creating the largest Oncology specific and patient-centric point-of-care network in the U.S. The two companies will still maintain operational independence while HMN will exclusively represent the combined network of nearly 15,000 high ... (more)

A sensitive new DNA test can predict how long ovarian cancer patients will survive, and guide personalized treatment decisions, according to new research.

Roche and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners' DARPin A biologics conjugated to toxic agents developed at Roche for the treatment of cancer.

The meeting will be held The studies highlight Eisai's current and ongoing clinical research efforts with eribulin mesylate, and reinforce the Company's commitment to metastatic breast cancer.

Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding OncoMed Pharmaceuticals, Inc. and Clovis Oncology, Inc. .

The affiliation agreement, if approved, aims to find ways for Ann Arbor-based University of Michigan Health System to work with Allegiance Health, which serves the Jackson area.

November was Lung Cancer Awareness Month, but you'd never know it. Consumers aren't bombarded by products in blue, the color designated by some to raise the profile of the disease.

Correspondence: Dr D Weisdorf, Division of Hematology-Oncology and Transplantation, Department of Medicine, University of Minnesota, 14-142 PWB, 516 Delaware, Street SE, Minneapolis, MN 55455, USA.

Minister of Health, John Boyce , noted that those cancers which were of particular public concern were cancers of the prostate, breast, cervix and colon which were attributable to premature deaths in persons under 65 years of age.

MEDIAN Technologies , a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials and clinical routine, today announced it has signed a three-year collaborative agreement with South Texas Accelerated Research Therapeutics .

Wake Forest Baptist Medical Center's new Comprehensive Cancer Center, which will open to patients next week, represents a $125 million expansion.

Presage Biosciences is one company that hopes to pioneer this personalized and data-driven approach, which they call " precision oncology."

"In late September/early October, he was diagnosed with metastatic liver cancer.

Dorathy Senay's doctor had some bad news after her last checkup, but it wasn't about her serious blood disorder called amyloidosis.

Among those expected to attend the event are Dr. John D. McConnell, Wake Forest Baptist Medical Center CEO, and Lorrie Apel, wife of a former cancer patient.

Three months after a thyroidectomy to remove cancer and one month after radioactive iodine to treat it, Julie Seitz found herself in an operating room again, this time for a lumpectomy to remove breast cancer.

WITH months to go before a dedicated unit for young people with cancer opens in the city its fundraising appeal has reached 2 million.

From left, Clare Looser-Frederking, Gaye Sponamore and Julie Wentz prepare to lift their 140-pound patient, Newfoundland Molly, off the table, also called the "couch," where she laid to receive radiation treatment for bone cancer at the Mizzou Animal Cancer Care facility in Wentzville.

Hemangini Shah, DO, a radiation oncologist at Kimball Medical Center, a Barnabas Health facility, was recently appointed to serve a three-year term as Cancer Liaison Physician for the cancer program at Kimball, which is accredited by the American College of Surgeons Commission on Cancer , a consortium of professional organizations designed to ... (more)

The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant, resulting in 22 percent of patients developing graft-vs.-host disease compared to 42 percent of patients who typically develop this condition with standard medications alone.